Related Experiment Video
Updated: May 31, 2025
08:18
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
Published on: December 26, 2015
17.3K
Fatigue relief in multiple sclerosis by personalized neuromodulation: A multicenter pilot study [FaremusGE]
Franca Tecchio1, Massimo Bertoli2, Elvira Sbragia3
1Laboratory of Electrophysiology for Translational neuroScience (LET'S), Istituto di Scienze e Tecnologie della Cognizione (ISTC), Consiglio Nazionale delle Ricerche (CNR), Rome, Italy.
Multiple Sclerosis and Related Disorders
|January 22, 2025
Summary
Faremus, a 5-day neuromodulation treatment, is a safe and effective option for reducing fatigue in multiple sclerosis (MS) patients. This pilot study confirms its feasibility and acceptance in a multicenter setting, improving quality of life.
Area of Science:
- Neurology
- Neuroscience
- Medical Devices
Background:
- Transcranial direct current stimulation (tDCS) shows promise for alleviating fatigue in multiple sclerosis (MS).
- The GRADE guidelines suggest neuromodulation as a recommendable intervention for MS-related fatigue.
Purpose of the Study:
- To assess the feasibility, acceptance, safety, and effectiveness of the Faremus neuromodulation treatment in a multicenter setting.
- To evaluate the patient and healthcare professional experience with the Faremus intervention.
Main Methods:
- A pilot, multicenter study involving 17 patients with multiple sclerosis (MS).
- The Faremus treatment involved 5 days of 15-minute daily tDCS.
- Intervention preparation and electrode supply were managed by a central unit; treatment delivery occurred at a participating hospital.
Main Results:
- All 17 participants completed the Faremus treatment, demonstrating high acceptance and safety.
- Fatigue symptoms improved by an average of 27%, and mild depressive symptoms improved by 38%.
- Healthcare professionals reported high satisfaction with the intervention (average score 8/10).
Conclusions:
- The personalized electroceutical intervention, Faremus (5-day anodal tDCS), is feasible, safe, and effective in a multicenter setting for MS fatigue.
- Faremus offers a reliable tool to improve quality of life for fatigued individuals with MS.
- This study supports the expansion of Faremus to multiple MS centers nationwide for patient benefit.
